Drug Trial Radar · NCT07371429
A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Sep 18, 2026
Primary completion
Aug 23, 2027
Study completion Aug 23, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will be conducted to evaluate how a single oral dose of Gepotidacin is processed in the body over time along with safety monitoring in hospitalized pediatric participants who are receiving a standard of care treatment with antibacterials for a confirmed or suspected infection or for its prevention.
Conditions
- Urinary Tract Infections
Interventions
GepotidacinDrug
Gepotidacin will be administered
SOCDrug
SOC will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC from time zero to the time of the last quantifiable concentration (AUC[0-t]) of gepotidacinTime frame: Up to 24 hours post dose (Day 1)
- Area under the concentration-time curve from time zero extrapolated to infinite time (AUC[0-inf]) of gepotidacinTime frame: Up to 24 hours post dose (Day 1)
- Maximum observed plasma concentration (Cmax) of gepotidacinTime frame: Up to 24 hours post dose (Day 1)
- Apparent oral clearance (CL/F) of gepotidacinTime frame: Up to 24 hours post dose (Day 1)
- Apparent volume of distribution (Vz/F) of gepotidacinTime frame: Up to 24 hours post dose (Day 1)
- Terminal phase half-life (t1/2) of gepotidacinTime frame: Up to 24 hours post dose (Day 1)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Orange, California
GSK Investigational Site
Shreveport, Louisiana
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.